BR112013002601A2 - corticosteróides para o tratamento de dor em articulação - Google Patents
corticosteróides para o tratamento de dor em articulaçãoInfo
- Publication number
- BR112013002601A2 BR112013002601A2 BR112013002601A BR112013002601A BR112013002601A2 BR 112013002601 A2 BR112013002601 A2 BR 112013002601A2 BR 112013002601 A BR112013002601 A BR 112013002601A BR 112013002601 A BR112013002601 A BR 112013002601A BR 112013002601 A2 BR112013002601 A2 BR 112013002601A2
- Authority
- BR
- Brazil
- Prior art keywords
- corticosteroids
- caused
- pain
- treatment
- osteoarthritis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
corticosteróides para o tratamento de dor em articulação. são proporcionadas formulações de micropartículas de corticosteróide para uso no tratamento da dor, incluindo dor causada por doenças inflamatórias tal como osteoartrite ou artrite reumatóide, e para desacelerar, atrasar, ou reverter o dano estrutural em tecidos causado por uma doença antiinflamatória, por exemplo, dano a tecidos por uma doença antiinflamatória, por exemplo, dano aos tecidos articulares e/ou peri-articulares causado por osteoartrite ou atrite reumatóide. formulações de micropartículas de corticosteróide são administradas localmente como uma forma de dosagem de liberação sustentada (com ou sem um componente de liberação imediata) que resulta em eficácia acompanhada por efeito clinicamente insignificante ou não mensurável na produção endógena de cortisol.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37066610P | 2010-08-04 | 2010-08-04 | |
PCT/US2011/046601 WO2012019009A1 (en) | 2010-08-04 | 2011-08-04 | Corticosteroids for the treatment of joint pain |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112013002601A2 true BR112013002601A2 (pt) | 2016-06-07 |
Family
ID=45559826
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013002601A BR112013002601A2 (pt) | 2010-08-04 | 2011-08-04 | corticosteróides para o tratamento de dor em articulação |
Country Status (23)
Country | Link |
---|---|
US (8) | US20120282298A1 (pt) |
EP (2) | EP3701941A1 (pt) |
JP (3) | JP5873492B2 (pt) |
KR (2) | KR20180132159A (pt) |
CN (2) | CN107669640A (pt) |
AR (1) | AR082471A1 (pt) |
AU (1) | AU2011285691B2 (pt) |
BR (1) | BR112013002601A2 (pt) |
CA (2) | CA2807150C (pt) |
CL (1) | CL2013000347A1 (pt) |
CO (1) | CO6700827A2 (pt) |
ES (1) | ES2799419T3 (pt) |
IL (1) | IL224547B (pt) |
MX (1) | MX353466B (pt) |
MY (1) | MY171929A (pt) |
NZ (1) | NZ607797A (pt) |
RU (2) | RU2018100114A (pt) |
SG (3) | SG10201607891VA (pt) |
TW (2) | TWI548412B (pt) |
UA (1) | UA111162C2 (pt) |
UY (1) | UY33546A (pt) |
WO (1) | WO2012019009A1 (pt) |
ZA (1) | ZA201300831B (pt) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA111162C2 (uk) | 2010-08-04 | 2016-04-11 | Флекшен Терап'Ютікс, Інк. | Ін'єкційна композиція ацетоніду триамцинолону для лікування болю |
EP3199146B1 (en) | 2011-04-25 | 2019-07-17 | Shan Dong Luye Pharmaceutical Co., Ltd. | Risperidone sustained release microsphere composition |
EP3281631A1 (en) * | 2011-08-04 | 2018-02-14 | Flexion Therapeutics, Inc. | Corticosteroids for the treatment of joint pain |
US8927529B2 (en) | 2012-01-30 | 2015-01-06 | SpineThera | Treatment of back pain by injection of microparticles of dexamethasone acetate and a polymer |
BR112015017246B1 (pt) | 2013-01-23 | 2022-11-29 | Semnur Pharmaceuticals, Inc | Composição farmacêutica aquosa injetável, seu uso e seringa |
CA2909303C (en) | 2013-03-15 | 2021-10-19 | Tracy RICHEY | Sustained release microspheres and method of producing the same |
WO2014153384A1 (en) * | 2013-03-19 | 2014-09-25 | Flexion Therapeutics, Inc. | Corticosteroid formulations for the treatment of joint pain and methods of use thereof |
SG11201507751YA (en) * | 2013-03-21 | 2015-10-29 | Eupraxia Pharmaceuticals USA LLC | Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith |
WO2015018461A1 (fr) * | 2013-08-09 | 2015-02-12 | Genbiotech | Compositions therapeutiques comprenant d'acide hyaluronique |
WO2015080939A1 (en) * | 2013-11-27 | 2015-06-04 | Ethicon, Inc. | Absorbable polymeric blend compositions with precisely controllable absorption rates, processing methods, and dimensionally stable medical devices therefrom |
JP6460540B2 (ja) * | 2014-04-08 | 2019-01-30 | ディーエスエム アイピー アセッツ ビー.ブイ.Dsm Ip Assets B.V. | 関節障害の処置のために使用される生分解性ポリエステルアミド |
TWI772659B (zh) | 2015-01-21 | 2022-08-01 | 美商桑紐爾製藥公司 | 醫藥配方 |
EP3307247A1 (en) * | 2015-06-10 | 2018-04-18 | Evonik Röhm GmbH | Process for preparing a powder comprising a human coagulation factor protein and a lactic acid polymer |
MX2018003380A (es) | 2015-09-21 | 2018-08-16 | Teva Pharmaceuticals Int Gmbh | Formulaciones de olanzapina de liberacion sostenida. |
UY36948A (es) * | 2015-10-13 | 2017-05-31 | Flexion Therapeutics Inc | Formulaciones de corticosteroides para mantener concentraciones de corticosteroide en el líquido sinovial |
JP2018531951A (ja) | 2015-10-27 | 2018-11-01 | ユープラシア ファーマシューティカルズ インク. | 局所麻酔薬の徐放性製剤 |
EP3429594A1 (en) | 2016-03-14 | 2019-01-23 | Flexion Therapeutics, Inc. | Triamcinolone acetonide formulations for joint pain in diabetics |
WO2018112408A1 (en) * | 2016-12-15 | 2018-06-21 | Flexion Therapeutics, Inc. | Fluticasone formulations and methods of use thereof |
CN106727358A (zh) * | 2017-01-24 | 2017-05-31 | 广州帝奇医药技术有限公司 | 阿立哌唑及其衍生物的缓释组合物与该缓释组合物的制备方法 |
CN106983733A (zh) * | 2017-03-08 | 2017-07-28 | 江苏富泽药业有限公司 | 曲安奈德plga缓释微球注射剂、其制备方法及其在制备治疗骨关节炎疼痛药物中的应用 |
EP3595776A4 (en) * | 2017-03-17 | 2020-09-30 | Flexion Therapeutics, Inc. | FLUTICASONE SUSTAINED-RELEASE FORMULATIONS AND THEIR PROCEDURES FOR USE |
US10646443B2 (en) | 2017-03-20 | 2020-05-12 | Teva Pharmaceuticals International Gmbh | Sustained release olanzapine formulations |
KR102101969B1 (ko) * | 2017-09-06 | 2020-04-22 | (주)인벤티지랩 | 목시덱틴을 포함하는 마이크로 입자 및 이의 제조 방법 |
US20190336511A1 (en) * | 2018-05-02 | 2019-11-07 | Georgiy Brusovanik | Treatment for Inflammation and Pain with Reduced Gastro-Intestinal Side Effects Combining Methylprednisolone, Paracetamol, and Lansoprazole |
JP7463306B2 (ja) * | 2018-07-09 | 2024-04-08 | タイワン リポソーム カンパニー リミテッド | 関節内ステロイドの合併症を軽減する方法 |
RU2703257C1 (ru) * | 2018-12-04 | 2019-10-16 | Закрытое акционерное общество "СКАЙ ЛТД" | Способ лечения воспалительных процессов суставов и простатита |
CN109700770B (zh) * | 2019-01-31 | 2021-02-12 | 浙江圣兆药物科技股份有限公司 | 一种曲安奈德微球制剂及其制备方法 |
KR102377975B1 (ko) * | 2019-03-19 | 2022-03-23 | (주)리젠바이오텍 | 스테로이드계 약물을 포함하는 생분해성 고분자 미세입자 및 이의 제조 방법 |
WO2020189886A2 (ko) | 2019-03-19 | 2020-09-24 | (주)리젠바이오텍 | 스테로이드계 약물을 포함하는 생분해성 고분자 미세입자 및 이의 제조 방법 |
WO2020227353A1 (en) * | 2019-05-06 | 2020-11-12 | Fordoz Pharma Corp. | Injectable sustained-release formulations for treatment of joint pain and inflammation |
EP3976106A4 (en) | 2019-05-31 | 2023-01-11 | DOSE Medical Corporation | BIOERODABLE POLYESTER SPINE IMPLANTS AND METHODS OF USE THEREOF |
CN110237052B (zh) * | 2019-07-11 | 2021-07-13 | 苏州大学 | 一种醋酸曲安奈德缓释微球及其制备方法 |
CN111803647A (zh) * | 2020-08-14 | 2020-10-23 | 山东谷雨春生物科技有限公司 | 一种治疗退行性关节炎的药物及其制备方法 |
US20240100012A1 (en) | 2021-01-18 | 2024-03-28 | Mark Hasleton | Pharmaceutical dosage form |
GB202104224D0 (en) | 2021-03-25 | 2021-05-12 | Medincell | Pharmaceutical composition |
JP2024511072A (ja) * | 2021-03-26 | 2024-03-12 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 炎症性関節炎を調節するための免疫調節微粒子 |
EP4322923A1 (en) | 2021-04-16 | 2024-02-21 | Fondazione Istituto Italiano di Tecnologia | Polymeric microparticles for the local treatment of chronic inflammatory diseases |
US20240277654A1 (en) | 2021-07-06 | 2024-08-22 | Mark Hasleton | Treatment of serotonin reuptake inhibitor withdrawal syndrome |
WO2024085581A1 (ko) * | 2022-10-17 | 2024-04-25 | (주)인벤티지랩 | 염증성 질환의 치료 또는 예방을 위한 서방형 주사용 조성물 및 이의 제조 방법 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4293539A (en) | 1979-09-12 | 1981-10-06 | Eli Lilly And Company | Controlled release formulations and method of treatment |
US4530840A (en) * | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
US5700485A (en) * | 1992-09-10 | 1997-12-23 | Children's Medical Center Corporation | Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid |
WO1995011009A1 (en) | 1993-10-22 | 1995-04-27 | Genentech, Inc. | Method for preparing microspheres comprising a fluidized bed drying step |
AU684324B2 (en) | 1993-11-19 | 1997-12-11 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of biodegradable microparticles containing a biologically active agent |
DE69841984D1 (de) | 1997-09-05 | 2010-12-16 | Maruho K K | Zusammensetzung aus nanokapseln zur behandlung von intraarticulaeren erkrankungen |
JPH11222425A (ja) * | 1997-10-27 | 1999-08-17 | Ss Pharmaceut Co Ltd | 関節疾患治療用関節内投与製剤 |
TW577758B (en) * | 1997-10-27 | 2004-03-01 | Ssp Co Ltd | Intra-articular preparation for the treatment of arthropathy |
US6726918B1 (en) * | 2000-07-05 | 2004-04-27 | Oculex Pharmaceuticals, Inc. | Methods for treating inflammation-mediated conditions of the eye |
US6824822B2 (en) | 2001-08-31 | 2004-11-30 | Alkermes Controlled Therapeutics Inc. Ii | Residual solvent extraction method and microparticles produced thereby |
TWI290471B (en) | 2000-11-06 | 2007-12-01 | Asahi Kasei Corp | Cellulosic particles for pharmaceutical preparations |
KR100446101B1 (ko) * | 2000-12-07 | 2004-08-30 | 주식회사 삼양사 | 수난용성 약물의 서방성 제형 조성물 |
AU2002235253A8 (en) | 2000-12-21 | 2005-10-06 | Inhale Therapeutic Syst | Induced phase transition method for the production of microparticles containing hydrophilic active agents |
US20040022853A1 (en) | 2001-04-26 | 2004-02-05 | Control Delivery Systems, Inc. | Polymer-based, sustained release drug delivery system |
WO2004030659A1 (en) * | 2002-09-30 | 2004-04-15 | Acusphere, Inc. | Sustained release porous microparticles for inhalation |
WO2004034975A2 (en) | 2002-10-17 | 2004-04-29 | Alkermes Controlled Therapeutics, Inc. | Sustained release profile modification |
EP3103422A1 (en) | 2003-03-14 | 2016-12-14 | Intersect ENT, Inc. | Sinus delivery of sustained release therapeutics |
US20040224030A1 (en) * | 2003-05-06 | 2004-11-11 | Shastri Venkatram R. | Microsphere delivery systems |
CA2528465A1 (en) | 2003-06-09 | 2005-01-20 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of growth hormone |
WO2005032523A1 (en) * | 2003-09-30 | 2005-04-14 | Acusphere, Inc. | Injectable, oral, or topical sustained release pharmaceutical formulations |
US7456254B2 (en) * | 2004-04-15 | 2008-11-25 | Alkermes, Inc. | Polymer-based sustained release device |
US8119154B2 (en) * | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
US20090324678A1 (en) * | 2004-07-16 | 2009-12-31 | Spinal Restoration, Inc. | Methods and kits for treating joints and soft tissues |
US7261529B2 (en) | 2005-09-07 | 2007-08-28 | Southwest Research Institute | Apparatus for preparing biodegradable microparticle formulations containing pharmaceutically active agents |
US9693967B2 (en) * | 2005-09-07 | 2017-07-04 | Southwest Research Institute | Biodegradable microparticle pharmaceutical formulations exhibiting improved released rates |
US7758778B2 (en) | 2005-09-07 | 2010-07-20 | Southwest Research Institute | Methods for preparing biodegradable microparticle formulations containing pharmaceutically active agents |
BRPI0615563A2 (pt) | 2005-09-07 | 2011-05-24 | Southwest Res Inst | formulações farmacêuticas em micropartìcula biodegradável exibindo taxas de liberação aperfeiçoadas |
US8663674B2 (en) | 2006-01-13 | 2014-03-04 | Surmodics, Inc. | Microparticle containing matrices for drug delivery |
US20070298073A1 (en) * | 2006-06-23 | 2007-12-27 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
EP2068845A2 (en) * | 2006-10-06 | 2009-06-17 | Baxter International Inc. | Microencapsules containing surface-modified microparticles and methods of forming and using the same |
US20080317805A1 (en) * | 2007-06-19 | 2008-12-25 | Mckay William F | Locally administrated low doses of corticosteroids |
US20090105142A1 (en) * | 2007-08-23 | 2009-04-23 | Genzyme Corporation | Treatment with kallikrein inhibitors |
US20110206773A1 (en) | 2008-05-20 | 2011-08-25 | Yale University | Sustained delivery of drugs from biodegradable polymeric microparticles |
US20110311630A1 (en) | 2008-06-09 | 2011-12-22 | Boehringer Ingelheim International Gmbh | Novel embedment particles for inhalation |
WO2010030868A1 (en) * | 2008-09-11 | 2010-03-18 | Surmodics Pharmaceuticals, Inc. | Solvent extraction microencapsulation with tunable extraction rates |
US20100189763A1 (en) | 2009-01-23 | 2010-07-29 | Heather Nettles | Controlled release systems from polymer blends |
EP2512487A4 (en) | 2009-12-15 | 2013-08-07 | THERAPEUTIC POLYMERNANOPARTICLES WITH CORTICOSTEROIDS AND METHOD FOR THE PRODUCTION AND USE THEREOF | |
UA111162C2 (uk) * | 2010-08-04 | 2016-04-11 | Флекшен Терап'Ютікс, Інк. | Ін'єкційна композиція ацетоніду триамцинолону для лікування болю |
-
2011
- 2011-04-08 UA UAA201301676A patent/UA111162C2/uk unknown
- 2011-08-03 TW TW100127548A patent/TWI548412B/zh active
- 2011-08-03 TW TW105118771A patent/TWI630001B/zh active
- 2011-08-03 AR ARP110102807A patent/AR082471A1/es unknown
- 2011-08-03 UY UY0001033546A patent/UY33546A/es not_active Application Discontinuation
- 2011-08-04 EP EP20170586.0A patent/EP3701941A1/en not_active Withdrawn
- 2011-08-04 CA CA2807150A patent/CA2807150C/en active Active
- 2011-08-04 RU RU2018100114A patent/RU2018100114A/ru not_active Application Discontinuation
- 2011-08-04 RU RU2013109362A patent/RU2642279C2/ru active
- 2011-08-04 MX MX2013001433A patent/MX353466B/es active IP Right Grant
- 2011-08-04 CN CN201710992399.XA patent/CN107669640A/zh active Pending
- 2011-08-04 CN CN201180047943.4A patent/CN103260603B/zh active Active
- 2011-08-04 KR KR1020187034479A patent/KR20180132159A/ko not_active Application Discontinuation
- 2011-08-04 CA CA2956556A patent/CA2956556A1/en not_active Abandoned
- 2011-08-04 BR BR112013002601A patent/BR112013002601A2/pt not_active Application Discontinuation
- 2011-08-04 SG SG10201607891VA patent/SG10201607891VA/en unknown
- 2011-08-04 ES ES11815323T patent/ES2799419T3/es active Active
- 2011-08-04 NZ NZ607797A patent/NZ607797A/en unknown
- 2011-08-04 SG SG10201602789XA patent/SG10201602789XA/en unknown
- 2011-08-04 WO PCT/US2011/046601 patent/WO2012019009A1/en active Application Filing
- 2011-08-04 EP EP11815323.8A patent/EP2600836B1/en active Active
- 2011-08-04 MY MYPI2013000361A patent/MY171929A/en unknown
- 2011-08-04 SG SG2013007703A patent/SG187665A1/en unknown
- 2011-08-04 JP JP2013523336A patent/JP5873492B2/ja active Active
- 2011-08-04 KR KR1020137004667A patent/KR101927551B1/ko active IP Right Grant
- 2011-08-04 AU AU2011285691A patent/AU2011285691B2/en active Active
-
2012
- 2012-02-08 US US13/368,580 patent/US20120282298A1/en not_active Abandoned
- 2012-03-16 US US13/422,994 patent/US8828440B2/en active Active
-
2013
- 2013-01-31 ZA ZA2013/00831A patent/ZA201300831B/en unknown
- 2013-02-03 IL IL224547A patent/IL224547B/en active IP Right Grant
- 2013-02-04 CL CL2013000347A patent/CL2013000347A1/es unknown
- 2013-03-04 CO CO13043214A patent/CO6700827A2/es unknown
- 2013-12-16 US US14/107,188 patent/US20140242170A1/en not_active Abandoned
-
2014
- 2014-08-18 US US14/461,883 patent/US9555047B2/en active Active
- 2014-08-18 US US14/461,884 patent/US9555048B2/en active Active
-
2015
- 2015-09-09 JP JP2015177143A patent/JP2016028070A/ja not_active Ceased
-
2017
- 2017-01-31 US US15/420,829 patent/US20170135957A1/en not_active Abandoned
- 2017-03-15 US US15/459,961 patent/US9949987B2/en active Active
-
2018
- 2018-03-27 US US15/937,053 patent/US10624905B2/en active Active
- 2018-11-29 JP JP2018223009A patent/JP2019059752A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013002601A2 (pt) | corticosteróides para o tratamento de dor em articulação | |
ECSP13012618A (es) | Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogénesis | |
BR112012030818A2 (pt) | "derivados de ácido c-3 betulínico modificado como inibidores da maturação do hiv" | |
NZ618734A (en) | Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas | |
MX346224B (es) | Composiciones y metodos para el tratamiento de inflamacion cronica y enfermedades inflamatorias. | |
UY32989A (es) | Coposiciones terapéuticas concentradas de fosfolípidos | |
BR112014006220A2 (pt) | composições de galacto-ramnogalacturonato para o tratamento de esteatohepatite não alcoólica e de doença de gordura no fígado não alcoólica | |
EA031157B9 (ru) | Вводимая перорально кортикостероидная композиция | |
PH12015500587A1 (en) | Combination of regorafenib and acetylsalicylic acid for treating cancer | |
SV2011003901A (es) | Compuestos de arilo con sustituyentes heterocíclicos como inhibidores de hif | |
BR112014020271A8 (pt) | Composição farmacêutica e métodos para diminuir a frequência de micção em paciente | |
BRPI0907028B8 (pt) | uso de 17a-acetóxi-11ß-[4-n,n-dimetilamino-fenil)-19-norpregna-4,9-dieno-3,20-diona | |
CO6620068A2 (es) | Anticuerpos monoclonales optimizados contra el inhibidor de la via del factor tisular (tfpi) | |
BR112019006880A2 (pt) | compostos e composições para tratamento de leishmaniose e métodos de diagnóstico e tratamen-to usando os mesmos | |
MX2012013607A (es) | Polisacarido de las semillas de tamarindo para usarse en el tatamiento de enfermedades inflamatorias. | |
BR112012022209A2 (pt) | composições farmacêuticas compreendendo monoterpenos | |
BR112015001627A2 (pt) | composição farmacêutica, respectivos usos e método para diminuir a frequência de micção | |
AR083095A1 (es) | Cocristal de aprepitant l-prolina y composicion farmaceutica | |
ECSP13012369A (es) | Agentes terapéuticos 976 | |
CO6602160A2 (es) | Terapia de b12 oral | |
WO2011127482A3 (en) | Modulation of histone deacetylases for the treatment of metabolic disease, methods and compositions related thereto | |
TR201010074A1 (tr) | Flurbiprofen, glukosamin ve kondroitin topikal farmasötik jel bileşimleri. | |
MX2009006614A (es) | Un procedimiento para preparar una composicion farmaceutica que contiene los principios activos glucosamina y meloxicam y el uso de dicha composición para el tratamiento de patologias degenerativas osteo-articulares. | |
WO2011159254A3 (en) | The use of des-aspartate-angiotensin i in inflammation-related pathologies and diseases | |
CL2011000095A1 (es) | Uso de una forma de dosificacion que comprende un descongestionante y un corticoesteroide para preparar un medicamento util para tratar o aliviar uno o mas sintomas de una condicion alergica o inflamatoria; forma de dosificacion. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |